Literature DB >> 10550849

The relative bioavailability of metoprolol following oral and rectal administration to volunteers and patients.

F M de Stoppelaar1, L M Stolk, A J Beysens, J L Stappers, A P Gorgels.   

Abstract

The pharmacokinetics, efficacy and safety of metoprolol tartrate 25 mg fatty suppositories were studied in 5 healthy volunteers and in 8 patients suffering from instable angina pectoris. Metoprolol 25 mg capsules were used as a control oral dosage form. Metoprolol showed a considerable rectal bioavailability (AUC, C max) and was absorbed quickly from the rectum (T max). In both groups rectal bioavailability was comparable. However, oral bioavailability was much lower in the volunteer group than in the patient group. Furthermore, ratios of metoprolol/alpha-OH-metoprolol concentrations in plasma and urine gave an indication for a partial avoidance of the first pass effect after rectal administration. Further research is necessary to define an exact rectal dosage of metoprolol. In all patients, a substantial drop in heart rate, systolic and diastolic blood pressure was seen after administration of the first suppository. Metoprolol suppositories appear to be an effective, safe and suitable alternative for patients who are in need for beta blocking medication and who are unable to take oral medication for a certain amount of time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10550849     DOI: 10.1023/a:1008792421982

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  15 in total

Review 1.  Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article.

Authors:  A Sandberg; B Abrahamsson; C G Regårdh; I Wieselgren; R Bergstrand
Journal:  J Clin Pharmacol       Date:  1990-02       Impact factor: 3.126

2.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

Authors:  S V Otton; H K Crewe; M S Lennard; G T Tucker; H F Woods
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

3.  Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man.

Authors:  E Cid; F Mella; L Lucchini; M Cárcamo; J Monasterio
Journal:  Biopharm Drug Dispos       Date:  1986 Nov-Dec       Impact factor: 1.627

4.  Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.

Authors:  M S Lennard; J H Silas; S Freestone; J Trevethick
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

5.  Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.

Authors:  C G Regårdh; L Jordö; M Ervik; P Lundborg; R Olsson; O Rönn
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

6.  Oxidation phenotype--a major determinant of metoprolol metabolism and response.

Authors:  M S Lennard; J H Silas; S Freestone; L E Ramsay; G T Tucker; H F Woods
Journal:  N Engl J Med       Date:  1982-12-16       Impact factor: 91.245

Review 7.  Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs.

Authors:  E van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

8.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

Authors:  J C McGourty; J H Silas; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

9.  Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.

Authors:  R E Jonkers; R P Koopmans; E J Portier; C J van Boxtel
Journal:  J Pharmacol Exp Ther       Date:  1991-03       Impact factor: 4.030

Review 10.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

View more
  1 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.